Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
The Holland Sweetener Co. vs. NutraSweet (E) (Spanish version)
Brandenburger, Adam; Costello, Maryellen; Kou, JuliaCaso HBS-703S19Dirección estratégicaSupplements the (A) case.Desde 5,74 €
-
Kathy Giusti and the Multiple Myeloma Research Foundation
Hamermesh, Richard G.; Margolis, Joshua D.; Preble, MatthewCaso HBS-814026-EServicios y operacionesWhat do you do when your rising professional career is cut short by an unexpected cancer diagnosis? Kathy Giusti shifted careers, built a new organization that transformed how cancer research is done, and now faces the challenge of sustaining the organization and its funding for its newest venture. Since she was first diagnosed with multiple myeloma (MM) in 1996, Giusti had led an effort to better understand and treat the disease. She had co-fou...Desde 8,20 €
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Caso HBS-302S36Conocimiento y comunicaciónDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Desde 8,20 €
-
Bloodbuy
Hamermesh, Richard G.; Norris, MichaelCaso HBS-815114-EIniciativa emprendedoraIn 2015, Chris Godfrey, founder and CEO of Bloodbuy has to consider the best path to growth for his young company that is attempting to disrupt the blood donation industry.Desde 8,20 €
-
Amylin Pharmaceuticals B
Hamermesh, Richard G.; Knoop, Carin-IsabelCaso HBS-813091-EIniciativa emprendedoraSupplement for case 809011Desde 8,20 €
-
Novasys Medical
Hamermesh, Richard G.; Barley, LaurenCaso HBS-810027-EIniciativa emprendedoraNovasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the product for reimbursement. The case deals with the company's struggle to obtain a reimbursement code.Desde 8,20 €
-
Medalogix
Hamermesh, Richard G.; Preble, MatthewCaso HBS-815116-EIniciativa emprendedoraThis case examines an exciting new approach to health care that will help care providers identify when hospice services are the appropriate type of care for patients. The company, Medalogix, already has a product on the market that uses a proprietery algorithm to consider dozens of factors and determine when a patient qualifies for a hospice care eligability review. The product has started to gain traction, and the case explores how Medalogix can...Desde 8,20 €
-
Impact Investing for Cancer
Hamermesh, Richard G.; Preble, MatthewCaso HBS-818068-EDirección estratégicaDesde 8,20 €
-
Gene Patents (A)
Hamermesh, Richard G.; Kiron, David; Andrews, PhillipCaso HBS-811089-EIniciativa emprendedoraIn March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.Desde 8,20 €
-
MedImmune Ventures
Hamermesh, Richard G.; Lane, DavidCaso HBS-814023-EIniciativa emprendedoraRon Laufer is the new Senior Managing Director of MedImmune Ventures', the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer will make will reflect his vision for MedImmune Ventures and more broadly the incentives he faces as a corporate venture capitalist.Desde 8,20 €